Elizabeth Holmes, the founder and former CEO of Theranos, was convicted on four counts of defrauding investors and later sentenced to more than a decade in federal prison. The case dismantled the story of a college dropout who claimed to have reinvented blood testing and became one of the most celebrated women in American business before her company collapsed. Holmes dropped out of Stanford’s School of Engineering in 2004 and used her tuition money to launch a consumer health technology company that eventually became Theranos. The company claimed it had developed devices capable of running a full range of blood tests using only a few drops of blood from a finger prick.
Holmes said her fear of needles motivated her pursuit of a less invasive testing method. Early skepticism from medical experts did not stop her. Stanford professor Phyllis Gardner told Holmes her idea would not work, but Holmes convinced engineering dean Channing Robertson to back her. Robertson became the company’s first board member and introduced her to venture capitalists.
By the end of 2010, Theranos had raised more than $92 million in venture capital. Holmes modeled herself publicly after Apple co-founder Steve Jobs, frequently wearing black turtlenecks and speaking in a deep baritone voice. Former employees and some experts later questioned the voice, though her family insisted it was genuine. The company operated in secrecy for years before announcing a partnership with Walgreens in 2013 to open in-store blood collection centers.
Theranos soon drew glowing media coverage. In 2014, Forbes named Holmes the youngest self-made female billionaire in America, valuing the company at $9 billion. She appeared on the covers of major business magazines, and her name appeared on dozens of U. S.
and foreign patents. The collapse began in October 2015, when The Wall Street Journal published a bombshell investigation by reporter John Carreyrou. The article revealed that Theranos’ signature Edison testing device produced inaccurate results and that the company relied on commercially available machines made by other manufacturers for most of its testing. Holmes and her lawyer, David Boies, had tried to block the article’s publication using legal and financial threats against the newspaper and former employees who spoke out.
Holmes publicly denied the allegations and dismissed the Journal as a tabloid. She appeared on CNBC’s Mad Money, where she compared criticism of her company to the resistance faced by innovators who later changed the world. Regulatory problems followed quickly. In 2016, federal health officials delivered a warning letter after inspecting a Theranos laboratory in California.
By July of that year, regulators barred Holmes from owning or operating a blood testing service for two years. Walgreens cut ties with the company, and the FDA ordered Theranos to stop using one of its main testing devices. In 2017, Arizona sued Theranos, alleging the company sold 1. 5 million blood tests to residents while concealing problems with those tests.
The company settled by refunding consumers and paying fines and attorney fees totaling $4. 65 million. In March 2018, the SEC charged Holmes and former Theranos president Ramesh “Sunny” Balwani with defrauding investors out of more than $700 million. The SEC said the company made false claims, including that its technology was used in combat by the U.
S. Department of Defense. Theranos also claimed a $100 million revenue stream in 2014 when it had actually generated only about $100,000. Holmes settled the SEC case by giving up voting control of the company, returning millions of shares, paying a $500,000 fine, and accepting a ten-year ban from serving as an officer or director of a public company.
The company shrank rapidly. After employing roughly 800 people at its peak, Theranos laid off hundreds of workers in late 2016 and early 2017. In September 2018, the company formally announced it was dissolving and distributing its remaining assets to creditors. A federal grand jury indicted Holmes and Balwani in June 2018 on nine counts of wire fraud and two counts of conspiracy to commit wire fraud.
Both pleaded not guilty. Prosecutors accused the pair of running one scheme that defrauded investors and another that defrauded doctors and patients. Holmes’ trial began in August 2021 in a federal court in California after delays caused by the COVID-19 pandemic and her pregnancy. She testified in her own defense over seven days, claiming that her staff misled her about the technology and that Balwani, her former romantic partner, exerted influence over her during the period of the alleged crimes.
Evidence presented by prosecutors included staged demonstrations, falsified validation reports, and overstated financials. On January 3, 2022, a jury found Holmes guilty of four counts: three counts of wire fraud and one count of conspiracy to commit wire fraud. She remained free on bail while awaiting sentencing. U.
S. District Judge Edward Davila sentenced Holmes on November 18, 2022, to 11 years in prison, with credit for good behavior potentially reducing the term. He ordered her to surrender to prison by April 2023 and suggested she serve her sentence at a low-security women’s facility in Texas.
Balwani was also convicted and received a longer sentence than Holmes after his own separate trial.